Evaluation of mitoxantrone for the treatment of multiple sclerosis

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.9, Iss.5, 2000-05, pp. : 1139-1149

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Intrathecal triamcinolone is more beneficial than IV mitoxantrone for the treatment of chronic progressive multiple sclerosis (MS)

Inpharma, Vol. 1, Iss. 1559, 2006-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Mitoxantrone: A Review of its Use in Multiple Sclerosis

By Scott L.J. Figgitt D.P.

CNS Drugs, Vol. 18, Iss. 6, 2004-01 ,pp. : 379-396

Adis International

Access to resources Recommend Favorite

Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain

By Tanasescu Radu Constantinescu Cris S

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 9, 2013-09 ,pp. : 1219-1228

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis

By Wiese Michael D

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 8, 2013-08 ,pp. : 1025-1035

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis

By Tanasescu Radu Constantinescu Cris S

Expert Opinion on Drug Metabolism and Toxicology, Vol. 10, Iss. 4, 2014-04 ,pp. : 621-630

Informa Healthcare

Access to resources Recommend Favorite